Arcus Biosciences Inc Cash Flow Conversion Efficiency
Arcus Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has a cash flow conversion efficiency ratio of -0.263x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-138.00 Million) by net assets ($524.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Arcus Biosciences Inc (2016–2025)
Cash flow conversion efficiency of Arcus Biosciences Inc from 2016 to 2025. This chart illustrates how Arcus Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Arcus Biosciences Inc (RCUS) share price today for real-time trading data and today's change.
Arcus Biosciences Inc Cash Flow Conversion Ratio Explained
Arcus Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arcus Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcus Biosciences Inc ranked by their cash flow conversion efficiency. Also see RCUS market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CSG Systems International Inc
NASDAQ:CSGS
|
-0.004x |
|
SOC.BIC UNS.ADR1/2/EO382
F:BIF0
|
N/A |
|
Lakala Payment Co Ltd
SHE:300773
|
0.037x |
|
Grupo Aeroméxico, S.A.B. de C.V.
NYSE:AERO
|
-0.252x |
|
Slide Insurance Holdings, Inc. Common Stock
NASDAQ:SLDE
|
0.026x |
|
Liveramp Holdings Inc
NYSE:RAMP
|
0.017x |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
-0.034x |
|
Grindwell Norton Limited
NSE:GRINDWELL
|
0.090x |
Annual Cash Flow Conversion Efficiency for Arcus Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arcus Biosciences Inc from 2016 to 2025. Review Arcus Biosciences Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $631.00 Million | $-482.00 Million | -0.764x | -117.93% |
| 2024-12-31 | $485.00 Million | $-170.00 Million | -0.351x | +47.08% |
| 2023-12-31 | $462.00 Million | $-306.00 Million | -0.662x | -199.35% |
| 2022-12-31 | $657.00 Million | $438.00 Million | 0.667x | +318.98% |
| 2021-12-31 | $841.45 Million | $-256.17 Million | -0.304x | -237.56% |
| 2020-12-31 | $502.30 Million | $111.17 Million | 0.221x | +149.36% |
| 2019-12-31 | $163.84 Million | $-73.46 Million | -0.448x | -145.00% |
| 2018-12-31 | $234.94 Million | $-43.00 Million | -0.183x | -12.37% |
| 2017-12-31 | $153.87 Million | $-25.06 Million | -0.163x | -25.14% |
| 2016-12-31 | $99.46 Million | $-12.94 Million | -0.130x | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more